We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Assay Developed to Measure Anti-Factor VIII Antibodies

By LabMedica International staff writers
Posted on 21 Nov 2022
Print article
Image: The compact xMAP INTELLIFLEX system is a flow-based, multiplex platform that simplifies the workflow by combining the established performance of xMAP technology (Photo courtesy of Thermo Fisher Scientific)
Image: The compact xMAP INTELLIFLEX system is a flow-based, multiplex platform that simplifies the workflow by combining the established performance of xMAP technology (Photo courtesy of Thermo Fisher Scientific)

Hemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints or the brain.

The development of neutralizing (inhibitors) and non-neutralizing antibodies (NNAs) is a complication to factor replacement therapy in hemophilia. The diagnostic methods available lack standardization, have high inter-laboratory variation, and false-negative as well as false-positive results may affect treatment.

Medical Laboratory Scientists at the University and Regional Laboratories Region Skåne (Skåne, Sweden) analyzed 112 samples obtained from patients with hemophilia A. They developed a diagnostic approach for measuring neutralizing inhibitors and non-neutralizing antibodies (NNAs) to factor VIII (FVIII) based on the xMAP-based fluorescence immunoassay (xFLI, Luminex Corporation, Austin, TX, USA).

The diagnostic approach developed by the scientists involved an xFLI system that they prepared in the laboratory. With this approach, they used commercially available FVIII concentrates coupled to dye-labeled magnetic beads, which could then be used for immunoassays. The FVIII concentrates were a full-length product (Advate, Lexington, MA, USA) and a product lacking in B domain (NovoEight, Plainsboro, NJ, USA). They compared xFLI-based results with those obtained using an enzyme-linked immunosorbent assay (ELISA) and another approach called the chromogenic Bethesda-Nijmegen Assay (CBA).

The investigators reported that the xFLI system using Advate FVIII concentrate showed a statistically significant correlation with the ELISA system in detecting anti-FVIII antibodies. In analyses of 86 samples, the xFLI system using Advate also showed a significant correlation with results from the CBA system for detecting anti-FVIII antibodies. In investigations comparing the xFLI system with NovoEight FVIII concentrate, significant correlations were also seen with the ELISA approach and with the CBA approach.

Analyses using ELISA and CBA methods demonstrated a concordance of 69.8% with each other. Overall concordance between the xFLI system and the ELISA approach was calculated to be 82.1%, and between the xFLI system and for the CBA approach it was 77.9%. Sensitivity also appeared improved with xFLI than with both ELISA and CBA approaches.

The authors concluded that the anti-FVIII antibody xFLI method is adaptable to clinical practice and more sensitive and reproducible than ELISA and CBA. Actual NNA titers were determined to both full-length and B-domain deleted FVIII. The xFLI is thus valuable for confirmation of all anti-FVIII antibodies. The study was published on October 3, 2022 in the journal Haemophilia.

Related Links:
University and Regional Laboratories Region Skåne 
Luminex Corporation 
Advate 
NovoEight 

Gold Supplier
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
New
H. pylori Test
H. pylori Antigen Rapid Test Kit
New
Automated Sample Preparation System
ASPEC 241
New
Lipase Assay
Lipase Assay

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.